Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Documenta Ophthalmologica
Published in: Documenta Ophthalmologica 1/2016

01-08-2016 | Original Research Article

The effect of cilostazol on electrophysiologic changes in non-proliferative diabetic retinopathy patients

Authors: Hoon Dong Kim, Si Hyoung Lee, Yoon Kyoung Kim, Jong Rok Oh, Young-Hoon Ohn

Published in: Documenta Ophthalmologica | Issue 1/2016

Login to get access

Abstract

Purpose

To evaluate the effects of cilostazol, an antiplatelet and vasodilation agent, on the retinal function of patients with non-proliferative diabetic retinopathy (NPDR) using a full-field electroretinogram (ffERG).

Methods

A total of 20 eyes from 20 patients were enrolled as the cilostazol-treated group, and 16 eyes from 16 patients were enrolled as the control group to assess the functional effects of cilostazol. Ophthalmologic examinations including fundus fluorescein angiography (FFA), fundus color photography, optical coherence tomography (OCT), and ffERG responses were recorded at baseline and after 1 year of cilostazol treatment. The number of microaneurysms on FFA, the number of exudates on fundus photographs, and central macular thickness (CMT) on OCT were compared between the two groups. Recording of ffERG was also performed at baseline and repeated after 1 year of treatment. The mean implicit times and amplitudes of a- and b-waves in each ffERG response were analyzed to evaluate the retinal function.

Results

CMT and the numbers of microaneurysms and exudates showed no significant change in the cilostazol-treated group. There was no significant change in ffERG parameters between baseline and 1 year after the treatment in each group. The mean changes in implicit times from the cilostazol-treated group were significantly less than in the control group in b-waves from dark-adapted 3 ERG (p = 0.017) and 10 ERG responses (p = 0.047). On the other hand, the mean changes in amplitudes were not significant after 1 year of cilostazol treatment, but there were slight increases in amplitudes of dark-adapted 0.01 ERG and 10 ERG in the cilostazol-treated group.

Conclusions

These results suggest that cilostazol administration could reduce the implicit times of ffERG in patients with NPDR. It may be beneficial to preserve the retinal function in the diabetic retina, and additional research with larger populations and extended duration are needed to clarify the efficacy and safety of cilostazol for these patients.
Literature
1.
2.
Malecki MT, Osmenda G, Walus-Miarka M et al (2008) Retinopathy in type 2 diabetes mellitus is associated with increased intima-media thickness and endothelial dysfunction. Eur J Clin Invest 38:925–930CrossRefPubMed
3.
Katakami N, Kim YS, Kawamori R et al (2010) The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation 121:2584–2591CrossRefPubMed
4.
Ahn CW, Lee HC, Park SW et al (2001) Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 52:45–53CrossRefPubMed
5.
Nishi T, Tabusa F, Tanaka T et al (1983) Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. II. 6-[3-(1-cyclohexyl-5-tetrazolyl)propoxy]-1,2-dihydro-2-oxoquinoline and related compounds. Chem Pharm Bull 31:1151–1157CrossRefPubMed
6.
Umekawa H, Tanaka T, Kimura Y et al (1984) Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography. Biochem Pharmacol 33:3339–3344CrossRefPubMed
7.
Tanaka T, Ishikawa T, Hagiwara M et al (1988) Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 36:313–320CrossRefPubMed
8.
Yamada N (1992) Clinical usefulness of cilostazol in patients with subjective symptoms caused by diabetes mellitus: multi-center Open Clinical Study. Jpn Pharmacol Ther 20:15–24
9.
Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820CrossRefPubMed
10.
Hammes HP, Lin J, Renner O et al (2002) Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 51:3107–3112CrossRefPubMed
11.
Jung KI, Kim JH, Park HY et al (2013) Neuroprotective effects of cilostazol on retinal ganglion cell damage in diabetic rats. J Pharmacol Exp Ther 345:457–463CrossRefPubMed
12.
Hotta H, Ito H, Kagitani F et al (1998) Cilostazol, a selective cAMP phosphodiesterase inhibitor, dilates retinal arterioles and increases retinal and choroidal blood flow in rats. Eur J Pharmacol 344:49–52CrossRefPubMed
13.
Early Treatment Diabetic Retinopathy Study Research Group (1991) Grading diabetic retinopathy from stereoscopic color fundus photographs–an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 98:786–806CrossRef
14.
Novo S (2002) Classification, epidemiology, risk factors, and natural history of peripheral arterial disease. Diabetes Obes Metab 4(Suppl 2):S1–S6CrossRefPubMed
15.
McCulloch DL, Marmor MF, Brigell MG et al (2015) ISCEV standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol 130:1–12CrossRefPubMed
16.
Tzekov R, Arden GB (1999) The electroretinogram in diabetic retinopathy. Surv Ophthalmol 44:53–60CrossRefPubMed
17.
Matsubara H, Kuze M, Sasoh M et al (2006) Time-dependent course of electroretinograms in the spontaneous diabetic Goto-Kakizaki rat. Jpn J Ophthalmol 50:211–216CrossRefPubMed
18.
Luu CD, Szental JA, Lee SY et al (2010) Correlation between retinal oscillatory potentials and retinal vascular caliber in type 2 diabetes. Invest Ophthalmol Vis Sci 51:482–486CrossRefPubMed
19.
Park SE, Sun HJ, Lee HJ et al (2010) The role of electroretinography in assessing the progression of diabetic retinopathy. J Korean Ophthalmol Soc 51:693–699CrossRef
20.
Bresnick GH, Palta M (1987) Oscillatory potential amplitudes. Relation to severity of diabetic retinopathy. Arch Ophthalmol 105:929–933CrossRefPubMed
21.
Parker JC, VanVolkenburg MA, Ketchum RJ et al (1995) Cyclic AMP phosphodiesterases of human and rat islets of Langerhans: contributions of types III and IV to the modulation of insulin secretion. Biochem Biophys Res Commun 217:916–923CrossRefPubMed
22.
Takazakura E, Ohsawa K, Hamamatsu K (1989) Effect of cilostazol (Pletaal) on serum lipid levels in diabetic patients. Jpn Pharmacol Ther 17:341–345
23.
Kashimoto R, Kurimoto T, Miyoshi T et al (2008) Cilostazol promotes survival of axotomized retinal ganglion cells in adult rats. Neurosci Lett 436:116–119CrossRefPubMed
24.
Kwak MS, Kim SH (1994) The electroretinogram a- and b-wave in diabetic retinopathy. J Korean Ophthalmol Soc 35:1081–1087
25.
Yonemura D, Aoki T, Tsuzuki K (1962) Electroretinogram in diabetic retinopathy. Arch Ophthalmol 68:19–24CrossRefPubMed
26.
Holopigian K, Seiple W, Lorenzo M et al (1992) A comparison of photopic and scotopic electroretinographic changes in early diabetic retinopathy. Invest Ophthalmol Vis Sci 33:2773–2780PubMed
Metadata
Title
The effect of cilostazol on electrophysiologic changes in non-proliferative diabetic retinopathy patients
Authors
Hoon Dong Kim
Si Hyoung Lee
Yoon Kyoung Kim
Jong Rok Oh
Young-Hoon Ohn
Publication date
01-08-2016
Publisher
Springer Berlin Heidelberg
Published in
Documenta Ophthalmologica / Issue 1/2016
Print ISSN: 0012-4486
Electronic ISSN: 1573-2622
DOI
https://doi.org/10.1007/s10633-016-9550-1

Other articles of this Issue 1/2016

Documenta Ophthalmologica 1/2016 Go to the issue

Clinical Case Report

Unilateral negative electroretinogram presenting as photophobia

Original Research Article

Exploring the methods of data analysis in multifocal visual evoked potentials

Original Research Article

Effect of shorter dark adaptation on ISCEV standard DA 0.01 and DA 3 skin ERGs in healthy adults

Original Research Article

Assessment of macular function, structure and predictive value of pattern electroretinogram parameters for postoperative visual acuity in patients with idiopathic epimacular membrane

Original Research Article

Abnormal 8-Hz flicker electroretinograms in carriers of X-linked retinoschisis

Original Research Article

Electrophysiological and clinical tests in dry age-related macular degeneration follow-up: differences between mfERG and OCT